Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism (Q38597498)

4 September 2017

Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism (English)

1 reference

chronic renal insufficiency

4 September 2017

1 reference

Murray Epstein

1

1 reference

4 September 2017

28 September 2015

1 reference

The Lancet: Diabetes & Endocrinology

4 September 2017

1 reference

4 September 2017

3

1 reference

4 September 2017

12

1 reference

4 September 2017

993-1003

1 reference

Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure

4 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Cardiovascular and noncardiovascular mortality among patients starting dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Prevalence of kidney damage in Australian adults: The AusDiab kidney study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: cause or association?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Chronic kidney disease: effects on the cardiovascular system

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Vascular calcification in chronic kidney disease: new developments in drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Arterial disease in chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Sudden cardiac death and dialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Sudden death and associated factors in a historical cohort of chronic haemodialysis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Cause-specific mortality of dialysis patients after coronary revascularization: why don't dialysis patients have better survival after coronary intervention?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Home blood pressures are of greater prognostic value than hemodialysis unit recordings

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Association between Inflammation and Cardiac Geometry in Chronic Kidney Disease: Findings from the CRIC Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Arterial calcification in chronic kidney disease: key roles for calcium and phosphate

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Blood pressure variability among chronic dialysis patients: recent advances in knowledge.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Statins in the management of dyslipidemia associated with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Blood pressure and mortality among hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

The uremic myocardium and ischemic tolerance: a world of difference

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Minireview: Aldosterone and mineralocorticoid receptors: past, present, and future

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Nongenomic actions of aldosterone and progesterone revisited

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

New aspects of rapid aldosterone signaling

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Non-genomic actions of aldosterone: from receptors and signals to membrane targets.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Evolving research in nongenomic actions of aldosterone

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Mineralocorticoid receptor-dependent proximal tubule injury is mediated by a redox-sensitive mTOR/S6K1 pathway

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Aldosterone blockade: an emerging strategy for abrogating progressive renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Mineralocorticoid receptor antagonists: part of an emerging treatment paradigm for chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Dietary salt intake. A determinant of cardiac involvement in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Chronic hyperaldosteronism in a transgenic mouse model fails to induce cardiac remodeling and fibrosis under a normal-salt diet

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

The role of tissue Renin-Angiotensin-aldosterone system in the development of endothelial dysfunction and arterial stiffness.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Increased cortisol metabolites and reduced activity of 11beta-hydroxysteroid dehydrogenase in patients on hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Eplerenone in patients with systolic heart failure and mild symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Effect of spironolactone on sex hormones in man

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

The evolution of aldosterone antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Nonsteroidal antagonists of the mineralocorticoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

A comparison of the aldosterone-blocking agents eplerenone and spironolactone

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁(c) levels in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Chronic kidney disease and heart failure--Bidirectional close link and common therapeutic goal

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney diseas

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Serum aldosterone and death, end-stage renal disease, and cardiovascular events in blacks and whites: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Role of aldosterone in left ventricular hypertrophy among African-American patients with end-stage renal disease on hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Rationale and design of the Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Rationale, Design, and Baseline Characteristics of ARTS-DN: A Randomized Study to Assess the Safety and Efficacy of Finerenone in Patients with Type 2 Diabetes Mellitus and a Clinical Diagnosis of Diabetic Nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Hyperkalemia as a constraint to therapy with combination Renin-Angiotensin system blockade: the elephant in the room

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Sodium zirconium cyclosilicate in hyperkalemia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900289-2

7 January 2021

10.1016/S2213-8587(15)00289-2

Identifiers

DOI

1 reference

4 September 2017

1 reference

PubMed ID

26429402